The company will deliver an oral presentation on ADRX-0405, its clinical-stage STEAP1 ADC, and a poster presentation on ADRX-0134, its preclinical Na ...

Presentations to highlight preclinical data supporting the clear differentiation of Adcentrx's clinical-stage ADRX-0405 STEAP1 ADC and preclinical ADRX-0134 NaPi2b ADC Adcentrx to present new ...

SAN DIEGO, March 25, 2025 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and ...

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured new developments in genitourinary radioligand therapy session and a presentation by Dr. Robert Flavell discussing STEAP1, DLL3, and CD46 ...

Adcentrx to present new preclinical data at AACR 2025 on the company’s novel ADRX-0405 STEAP1 & ADRX-0134 NaPi2b ADCs. The company will deliver an oral presentation on ADRX-0405, its clinical-stage ...

Adcentrx to present new preclinical data at AACR 2025 on the company's novel ADRX-0405 STEAP1 & ADRX-0134 NaPi2b ADCs. The company will deliver an oral presentation on ADRX-0405, its clinical ...

SAN DIEGO, March 25, 2025 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other ...

AbbVie (NYSE: ABBV) today announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming American Association of Cancer Research (AACR) Annual ...

Data for ABBV-969, a novel STEAP1/PSMA dual-targeted antibody-drug conjugate (ADC) in Phase 1 for advanced prostate cancer, will be presented in an oral presentation. Data to be presented on ABBV ...

艾伯维（NYSE: ...